Background: CDK4/6 inhibitor ribociclib was recently approved in the United States in combination with letrozole for the treatment of HRþ, HER2-ABC in postmenopausal women with no prior therapy for advanced disease, based on the significantly prolonged PFS versus placebo plus letrozole observed in the pivotal phase 3 MONALEESA-2 trial (Hortobagyi et al. NEJM 2016) . The phase 3b CompLEEment-1 study will further evaluate the safety and efficacy of ribociclib plus letrozole as first-line therapy in an expanded patient population.
Trial design:
In this open-label study, men or women of any menopausal status with HRþ, HER2-ABC will receive ribociclib (600 mg/day, 3 weeks on/1 week off) þ letrozole (2.5 mg/day); men and premenopausal women will receive concomitant goserelin (3.6 mg subcutaneous implant every 28 days). Treatment will continue until disease progression or unacceptable toxicity. Patients are limited to 1 line of chemotherapy and no prior ET for advanced disease; patients receiving (neo)adjuvant ET with a nonsteroidal aromatase inhibitor must have a disease-free interval of > 12 months. Exclusion criteria include Eastern Cooperative Oncology Group performance status >2, or prior CDK4/6 inhibitor treatment. Planned hematologic and chemistry laboratory assessments will be completed every 2 weeks for the first 2 months, then monthly to Cycle 6, and as clinically indicated to Cycle 36. Tumor assessments are recommended every 12 weeks or at intervals per local standard of care during the treatment phase. The primary outcome is safety and tolerability. Secondary outcomes include time to progression, clinical benefit rate, overall response rate, safety, and patient-reported outcomes (PROs). Adverse events and drug-drug interactions will be monitored using CT Scholar; PROs will be collected for female patients using the FACT-B questionnaire to better understand health-related quality of life and treatment side effects. Global recruitment of the planned 3,000 patients is ongoing, with the majority occurring in Europe. Clinical trial identification: NCT02941926 Legal entity responsible for the study: Novartis Pharmaceuticals Background: While TNBC patients with pCR/RCB-0 or RCB-1 have excellent survival, those with extensive residual disease (RCB-II or RCB-III) after NACT have poor prognosis. At MD Anderson, through the Moonshot Initiative, we have created a biomarker-driven drug development strategy, ARTEMIS (A Randomized, TNBC Enrolling trial to confirm Molecular profiling Improves Survival) to identify novel targeted therapies for tumors that are predicted to be insensitive to standard NACT. Molecular profiling along with imaging is used to identify patients with chemoinsensitive disease and inform second phase of therapy incorporating targeted agents to improve responses. Folate receptor a (FRa) is a GPI-anchored surface protein encoded by FOLR1 gene that is overexpressed in multiple cancers including TNBC. Mirvetuximab soravtansine is an antibody-drug conjugate that consists of a monoclonal antibody against FRa conjugated to maytansinoid, a microtubule inhibitor. Nearly 40% of TNBC express high levels of FRa, suggesting that FRa directed therapy is a viable therapeutic strategy. Trial design: The study will include a lead in cohort (Cohort A) to establish efficacy in metastatic TNBC patients and a neoadjuvant cohort (Cohort B) to determine activity in chemo-insensitive, localized TNBC patients. If > 2 patients in Cohort A have response, the neoadjuvant cohort will be activated. Patients deemed to have chemoinsensitive, FRaþ TNBC identified through the ARTEMIS are eligible for Cohort B. The primary objectives are to determine the response rate of single agent mirvetuximab in metastatic FRaþ TNBC (> 2 lines of therapy) and to determine if mirvetuximab would improve the rates of neoadjuvant pathologic response (pCR or RCB-I) from 5% to 20% in patients with high risk, chemo-insensitive, FRaþ TNBC. A two-stage Gehantype design with 14 patients in the first stage will be employed for the neoadjuvant cohort (n ¼ 37). Mirvetuximab will be given IV every 21 days (6 mg/kg). 
